Hilde Furberg, Guido Oelkers

Blueprint Genetics has appointed Hilde Furberg as chairman of its board of directors. Furberg previously served as head of rare disease Europe at Sanofi Genzyme. She is also currently an industrial advisor to Investinor and a board member of BerGenBio, Calliditas, and Tappin. Hilde has previously worked at companies including Baxter and Genzyme, and has also been a board member of Probi, Pronova, Clavis, and Algeta.

In addition, Blueprint has appointed Guido Oelkers as a senior advisor to the firm. Oelkers currently serves as CEO of Swedish Orphan Biovitirum. Previously, he served in roles including CEO of BSN Medical, CEO of Gambro, CEO of Invida, and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group, and Aventis.